生物标志物发现的肝细胞癌的分子和代谢表型:一个元分析
Nguyen Hoang Anh1, Nguyen Phuoc Long2, Young Jin Min1
1College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Metabolites
|November 24, 2023
概括
这项研究通过分析来自68个队伍的多组数据来确定强大的肝细胞癌 (HCC) 生物标志物. 它提出了一种数据驱动的方法,用于在癌症研究中可靠地发现生物标志物.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 肝细胞癌 (HCC) 生物标志物发现受到不一致的发现的挑战.
- 将实验室发现转化为临床实践需要强大的,经过验证的生物标志物.
研究的目的:
- 使用多组学元分析识别和验证可靠的肝细胞癌 (HCC) 生物标志物.
- 建立适用于各种疾病的生物标志物发现的数据驱动方法.
主要方法:
- 对68个队列的定量证据进行了元分析,重点关注系统性和以代谢为中心的多组学数据.
- 与HCC代谢表型相关的经验证和优先考虑的血液转录生物标志物.
- 分析了HCC与对照组,HCC与肝硬化 (LC) 和LC与对照组之间的代谢物和脂质资料.
主要成果:
- 在HCC中识别了经常报告的生物标志物,包括氨基酸,脂肪酸 (18:1),胆汁酸和酸醇.
- 发现了39种代谢物和52种脂质,这些代谢物和脂质在三个或更多的研究中报告了HCC与对照者的研究.
- 观察到BAX和RAC1基因表达与HCC预后不佳相关.
结论:
- 通过数据驱动的,基于知识的元分析,提出了一套强大的HCC生物标志物.
- 开发的方法对于在其他疾病中发现生物标志物来说是多功能和负担得起的.
- 突出了多组数据集成在促进癌症诊断方面的潜力.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...